FDA Issues Warning Letter to Novo Nordisk Inc. Regarding Postmarketing Safety Reporting

The U.S. Food and Drug Administration (FDA) has issued a Warning Letter to Novo Nordisk Inc. (NNI) following an inspection conducted between January and February 2025. The inspecti